Pre- and posttreatment head CTs with contrast in a patient with primary refractory PCNSL. (Left) The contrast-enhancing lesion before treatment with nivolumab. (Middle) Complete response following 2 months therapy with nivolumab. (Right) Continued complete response 13 months following initiation of therapy.